SI3122743T1 - Sestavki in metode za zdravljenje nevrodegenerativnih bolezni - Google Patents
Sestavki in metode za zdravljenje nevrodegenerativnih bolezniInfo
- Publication number
- SI3122743T1 SI3122743T1 SI201531921T SI201531921T SI3122743T1 SI 3122743 T1 SI3122743 T1 SI 3122743T1 SI 201531921 T SI201531921 T SI 201531921T SI 201531921 T SI201531921 T SI 201531921T SI 3122743 T1 SI3122743 T1 SI 3122743T1
- Authority
- SI
- Slovenia
- Prior art keywords
- compositions
- methods
- neurodegenerative diseases
- treating neurodegenerative
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461971862P | 2014-03-28 | 2014-03-28 | |
EP15769990.1A EP3122743B1 (en) | 2014-03-28 | 2015-03-27 | Compositions and methods for treating neurodegenerative diseases |
PCT/US2015/023060 WO2015148962A1 (en) | 2014-03-28 | 2015-03-27 | Compositions and methods for treating neurodegenerative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3122743T1 true SI3122743T1 (sl) | 2023-07-31 |
Family
ID=54196457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201531921T SI3122743T1 (sl) | 2014-03-28 | 2015-03-27 | Sestavki in metode za zdravljenje nevrodegenerativnih bolezni |
Country Status (22)
Country | Link |
---|---|
US (4) | US9802925B2 (sl) |
EP (1) | EP3122743B1 (sl) |
JP (2) | JP7255967B2 (sl) |
KR (2) | KR20220151037A (sl) |
CN (3) | CN106459021B (sl) |
AU (2) | AU2015237253B2 (sl) |
BR (1) | BR112016022575A2 (sl) |
CA (1) | CA2944211C (sl) |
DK (1) | DK3122743T3 (sl) |
ES (1) | ES2939959T3 (sl) |
FI (1) | FI3122743T3 (sl) |
IL (1) | IL248074B (sl) |
MX (2) | MX2021005502A (sl) |
MY (1) | MY184878A (sl) |
NZ (1) | NZ724718A (sl) |
PL (1) | PL3122743T3 (sl) |
RU (1) | RU2742773C2 (sl) |
SG (2) | SG11201608064WA (sl) |
SI (1) | SI3122743T1 (sl) |
TW (1) | TWI736519B (sl) |
WO (1) | WO2015148962A1 (sl) |
ZA (1) | ZA201606673B (sl) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2587919B1 (en) | 2010-07-01 | 2017-12-13 | Azevan Pharmaceuticals, Inc. | Methods for treating post traumatic stress disorder |
NZ724718A (en) | 2014-03-28 | 2023-04-28 | Azevan Pharmaceuticals Inc | Compositions and methods for treating neurodegenerative diseases |
TWI622380B (zh) * | 2017-01-17 | 2018-05-01 | 正崴精密工業股份有限公司 | 生理訊號測量裝置及其血氧濃度演算方法 |
CN111295373A (zh) | 2017-09-15 | 2020-06-16 | 阿泽凡药物公司 | 用于治疗脑损伤的组合物和方法 |
KR20230124992A (ko) * | 2020-12-23 | 2023-08-28 | 셀진 코포레이션 | 신경변성 질환의 치료를 위한 카르복실산 함유 인다닐화합물 |
WO2023164710A1 (en) * | 2022-02-28 | 2023-08-31 | The Trustees Of Columbia University In The City Of New York | Avpr1a blockade to reduce social isolation-induced anxiety in females |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1422263A (en) | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
US4314081A (en) | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
NL7503310A (nl) | 1975-03-20 | 1976-09-22 | Philips Nv | Verbindingen met antidepressieve werking. |
US4576753A (en) | 1975-10-06 | 1986-03-18 | Fujisawa Pharmaceutical Co., Ltd. | Azetidinone compounds and processes for preparation thereof |
GB1526331A (en) | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
US4341698A (en) | 1979-06-21 | 1982-07-27 | Richardson-Merrell Inc. | Enkaphalin derivatives |
US4536518A (en) | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
JPS6033439B2 (ja) | 1980-03-07 | 1985-08-02 | 財団法人相模中央化学研究所 | ジペプチドの製造方法 |
JPS56125361A (en) | 1980-03-07 | 1981-10-01 | Sagami Chem Res Center | Azetidinone compound |
FR2508035A1 (fr) | 1981-06-23 | 1982-12-24 | Fabre Sa Pierre | Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central |
US4761501A (en) | 1983-10-26 | 1988-08-02 | American Home Products Corporation | Substituted phenylacetamides |
US4751299A (en) | 1983-11-18 | 1988-06-14 | Takeda Chemical Industries, Ltd. | Optically active β-lactams and method of their production |
US4665171A (en) | 1985-07-17 | 1987-05-12 | Harvard University | Process and intermediates for β-lactam antibiotics |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US4734498A (en) | 1986-07-10 | 1988-03-29 | Eli Lilly And Company | 3β-succinimidoazetidinones as chiral intermediates |
US4772694A (en) | 1986-07-24 | 1988-09-20 | Eli Lilly And Company | Chiral 3-(1,2,5-trisubstituted imidazolidinone) azetidinone antibiotic intermediates |
US4956388A (en) | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
US5627165A (en) | 1990-06-13 | 1997-05-06 | Drug Innovation & Design, Inc. | Phosphorous prodrugs and therapeutic delivery systems using same |
WO1994004494A1 (en) | 1992-08-13 | 1994-03-03 | Warner-Lambert Company | Tachykinin antagonists |
EP0551432A1 (en) | 1990-10-02 | 1993-07-21 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1h-imidazo 4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists |
GB9204001D0 (en) | 1992-02-25 | 1992-04-08 | Jacobs Suchard Ag | Process for producing reduced fat nuts |
US5246943A (en) | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
WO1994001402A1 (en) | 1992-07-13 | 1994-01-20 | Merck Sharp & Dohme Limited | Heterocyclic amide derivatives as tachykinin derivatives |
FR2696178B1 (fr) | 1992-09-30 | 1994-12-30 | Sanofi Elf | Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant. |
DE69405862T2 (de) | 1993-05-06 | 1998-01-15 | Merrell Pharma Inc | Substituierte pyrrolidin-3-alkyl-piperidine verwendbar als tachykinin-antagonisten |
US5512563A (en) | 1993-07-29 | 1996-04-30 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
US5759865A (en) | 1995-05-03 | 1998-06-02 | Eli Lilly And Company | Combinatorial process for synthesizing azetidinone analogs |
GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
ES2248840T3 (es) | 1996-02-23 | 2006-03-16 | Eli Lilly And Company | Antagonistas de vasopresina v1a no peptidilicos. |
NZ502449A (en) | 1997-07-30 | 2002-08-28 | Wyeth Corp | Tricyclic vasopressin agonists and their pharmaceutical use |
US6403632B1 (en) | 2000-03-01 | 2002-06-11 | Bristol Myers Squibb Pharma Co | Lactam metalloprotease inhibitors |
CA2307820C (en) | 1997-10-27 | 2007-04-24 | Dr. Reddy's Research Foundation | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
CN1382047A (zh) | 1999-08-16 | 2002-11-27 | 雷瓦尔克斯药品有限公司 | 神经病治疗组合物和方法 |
GB0019006D0 (en) | 2000-08-04 | 2000-09-20 | Astrazeneca Ab | Novel compounds |
WO2003031407A2 (en) * | 2001-10-12 | 2003-04-17 | Serenix Pharmaceuticals, Llc | β-LACTAMYL VASOPRESSIN VlaANTAGONISTS |
AU2002359761A1 (en) | 2001-12-18 | 2003-06-30 | Invenux, Inc. | Antibiotic compounds |
US7135479B2 (en) | 2002-09-12 | 2006-11-14 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans |
GB0224919D0 (en) * | 2002-10-25 | 2002-12-04 | Pfizer Ltd | Triazole compounds useful in therapy |
NZ544200A (en) | 2003-07-14 | 2009-07-31 | Arena Pharm Inc | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
WO2005035492A1 (en) | 2003-10-03 | 2005-04-21 | Serenix Pharmaceuticals, Llc. | 3-SUBSTITUTED β-LACTAMYL VASOPRESSIN V1A ANTAGONISTS |
US7745630B2 (en) | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
EP1632494A1 (en) | 2004-08-24 | 2006-03-08 | Ferring B.V. | Vasopressin v1a antagonists |
EP1669776A1 (de) | 2004-12-11 | 2006-06-14 | Leica Geosystems AG | Handhaltbares Vermessungsgerät und Vermessungsverfahren für ein solches Vermessungsgerät |
FR2881744B1 (fr) | 2005-02-09 | 2007-04-27 | Sanofi Aventis Sa | Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique |
AU2006227199A1 (en) | 2005-03-22 | 2006-09-28 | Azevan Pharmaceuticals, Inc. | Beta-lactamylalkanoic acids for treating premenstrual disorders |
US20080234252A1 (en) | 2005-05-18 | 2008-09-25 | Pfizer Inc | Compounds Useful in Therapy |
AU2006270039B2 (en) | 2005-07-19 | 2013-07-04 | Azevan Pharmaceuticals, Inc. | Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists |
WO2007109615A2 (en) * | 2006-03-21 | 2007-09-27 | Azevan Pharmaceuticals, Inc. | β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS |
WO2008034032A2 (en) | 2006-09-14 | 2008-03-20 | Azevan Pharmaceuticals, Inc. | Beta-lactam cannabinoid receptor modulators |
US7825111B2 (en) | 2006-09-22 | 2010-11-02 | Janssen Pharmaceutica Nv | Substituted spiroheterocycles |
EP2173745A2 (en) | 2007-03-23 | 2010-04-14 | Array Biopharma, Inc. | 2-aminopyridine analogs as glucokinase activators |
FR2927625B1 (fr) * | 2008-02-19 | 2010-03-12 | Sanofi Aventis | Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique |
FR2930249B1 (fr) * | 2008-04-21 | 2010-05-14 | Sanofi Aventis | Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique. |
EP2587919B1 (en) * | 2010-07-01 | 2017-12-13 | Azevan Pharmaceuticals, Inc. | Methods for treating post traumatic stress disorder |
CA2901577A1 (en) | 2013-02-18 | 2014-08-21 | The Scripps Research Institute | Modulators of vasopressin receptors with therapeutic potential |
NZ724718A (en) | 2014-03-28 | 2023-04-28 | Azevan Pharmaceuticals Inc | Compositions and methods for treating neurodegenerative diseases |
CN111295373A (zh) | 2017-09-15 | 2020-06-16 | 阿泽凡药物公司 | 用于治疗脑损伤的组合物和方法 |
-
2015
- 2015-03-27 NZ NZ724718A patent/NZ724718A/en unknown
- 2015-03-27 DK DK15769990.1T patent/DK3122743T3/da active
- 2015-03-27 MX MX2021005502A patent/MX2021005502A/es unknown
- 2015-03-27 US US15/129,190 patent/US9802925B2/en active Active
- 2015-03-27 WO PCT/US2015/023060 patent/WO2015148962A1/en active Application Filing
- 2015-03-27 CN CN201580027324.7A patent/CN106459021B/zh active Active
- 2015-03-27 KR KR1020227038057A patent/KR20220151037A/ko not_active Application Discontinuation
- 2015-03-27 PL PL15769990.1T patent/PL3122743T3/pl unknown
- 2015-03-27 BR BR112016022575A patent/BR112016022575A2/pt not_active Application Discontinuation
- 2015-03-27 KR KR1020167028877A patent/KR20160130853A/ko active Application Filing
- 2015-03-27 MY MYPI2016703577A patent/MY184878A/en unknown
- 2015-03-27 ES ES15769990T patent/ES2939959T3/es active Active
- 2015-03-27 SI SI201531921T patent/SI3122743T1/sl unknown
- 2015-03-27 SG SG11201608064WA patent/SG11201608064WA/en unknown
- 2015-03-27 CN CN202310338535.9A patent/CN116327950A/zh active Pending
- 2015-03-27 JP JP2017502942A patent/JP7255967B2/ja active Active
- 2015-03-27 EP EP15769990.1A patent/EP3122743B1/en active Active
- 2015-03-27 MX MX2016012645A patent/MX2016012645A/es unknown
- 2015-03-27 CA CA2944211A patent/CA2944211C/en active Active
- 2015-03-27 AU AU2015237253A patent/AU2015237253B2/en active Active
- 2015-03-27 FI FIEP15769990.1T patent/FI3122743T3/fi active
- 2015-03-27 CN CN202310338451.5A patent/CN116139282A/zh active Pending
- 2015-03-27 RU RU2016138349A patent/RU2742773C2/ru active
- 2015-03-27 SG SG10202001065SA patent/SG10202001065SA/en unknown
- 2015-03-30 TW TW104110388A patent/TWI736519B/zh active
-
2016
- 2016-09-27 ZA ZA2016/06673A patent/ZA201606673B/en unknown
- 2016-09-27 IL IL248074A patent/IL248074B/en active IP Right Grant
-
2017
- 2017-10-18 US US15/786,772 patent/US10364236B2/en active Active
-
2019
- 2019-06-10 US US16/436,350 patent/US11319306B2/en active Active
- 2019-10-23 AU AU2019253831A patent/AU2019253831B2/en active Active
-
2022
- 2022-04-29 US US17/732,631 patent/US20230123729A1/en active Pending
- 2022-05-09 JP JP2022077195A patent/JP2022116001A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1225651A1 (zh) | 異吲哚啉組合物和治療神經變性疾病的方法 | |
HK1232141A1 (zh) | 用於治療亨廷頓病的方法和組合物 | |
IL255421A0 (en) | Preparations and methods for the treatment of neurodegenerative disease | |
SG11201705093UA (en) | Composition for treating il-6-related diseases | |
IL246791A0 (en) | Compositions and methods for treating eye diseases | |
EP2953950A4 (en) | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | |
LT3200815T (lt) | Būdai ir kompozicijos, skirti vėžio gydymui | |
IL247699A0 (en) | Preparations and methods for the treatment of kidney disorders | |
EP3139928A4 (en) | Anordrin compositions and methods for treating diseases | |
LT3189074T (lt) | Kompozicijos ir būdai skirti uždegimo gydymui ir prevencijai | |
IL249098A0 (en) | Methods and preparations for the treatment of allergy and inflammatory diseases | |
EP3110446A4 (en) | Methods and compositions for treating siglec-8 associated diseases | |
HK1245127A1 (zh) | 治療腦疾病的方法和組合物 | |
ZA201606199B (en) | Compositions and methods for treating diabetes and liver diseases | |
ZA201606673B (en) | Compositions and methods for treating neurodegenerative diseases | |
EP3164132A4 (en) | Methods and compositions for treating diseases and conditions | |
ZA201605109B (en) | Compositions and methods for treating neutropenia | |
HK1246206A1 (zh) | 用於治療青光眼的組合物和方法 | |
EP3107534A4 (en) | Compositions and methods for the treatment of neurodegenerative diseases | |
EP3364965A4 (en) | METHOD AND COMPOSITIONS FOR TREATING NEURODEEGENERATIVE DISEASES | |
HK1244782A1 (zh) | 用於治療疾病和病癥的組合物和方法 | |
GB201420348D0 (en) | Compounds for treating neurodegenerative diseases | |
GB201521083D0 (en) | Compositions for treatment and methods thereof | |
GB201419559D0 (en) | Therapeutic compositions and methods | |
SG10201400823PA (en) | Therapeutic methods and compositions for treating diabetes |